Dr. Holtzman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5150 Centre Avenue
Fl 4
Pittsburgh, PA 15232Phone+1 412-692-2852Fax+1 412-692-2520
Summary
- Dr. Matthew Holtzman is a general surgeon in Pittsburgh, PA and is affiliated with multiple hospitals in the area, including UPMC Magee-Womens Hospital, UPMC Presbyterian Shadyside - Shadyside, UPMC Passavant, UPMC Presbyterian, and UPMC Presbyterian Shadyside - Shadyside. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 18 years. He specializes in surgical oncology (other than breast) and minimally invasive surgery and is experienced in minimally invasive surgery, endocrine surgery, surgical oncology (non-breast), colorectal surgery, and general / gastrointestinal surgery.
Education & Training
- Boston University Medical CenterResidency, Surgery, 1999 - 2004
- State University of New York Downstate Medical Center College of MedicineClass of 1999
Certifications & Licensure
- PA State Medical License 2004 - 2024
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- 82 citationsInstitutional Learning Curve of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal MalignanciesPatricio M. Polanco, Ying Ding, Jordan M. Knox, Lekshmi Ramalingam, Heather Jones
Annals of Surgical Oncology. 2015-05-01 - 2 citationsNeoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Diwakar Davar, Robert M Morrison, Amiran K Dzutsev, Arivarasan Karunamurthy, Joe-Marc Chauvin
Cancer Cell. 2024-11-11 - 14 citationsNeoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Dustin McCurry, Huang Lin, Yan Lin, Yan Zang
Clinical Cancer Research. 2021-03-22
Journal Articles
- Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion Is Feasible and Offers Survival Benefit in Select Patients with Peritoneal MetastasesDavid L Bartlett, Filip Bednar, Reetesh K Pai, Heather L Jones, James F Pingpank, Matthew P Holtzman, Herbert J Zeh, Annals of Surgical Oncology
- Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal MalignanciesMatthew P Holtzman, James F Pingpank, David L Bartlett, Herbert J Zeh, Annals of Surgical Oncology
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: